Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia-related features with one 10-color 14-antibody screening tube
(2015) In Cytometry Part B - Clinical Cytometry 88(4). p.253-260- Abstract
Background We have designed one-tube 14-antibody 10-color flow cytometry (FCM) panel that would provide maximum information on lymphoid and myeloid cell subsets in bone marrow aspirates (BMA) from patients with cytopenia(s). Samples and Methods BMA from 8 normal donors, from 286 non-malignant hospital controls, 92 myelodysplastic syndromes (MDS), 47 myeloproliferative neoplasms (MPN), and from 14 MDS/MPN patients were investigated. One tube 14-monoclonal antibody (MAb) 10-fluorochrome panel included: kappa+CD4 FITC, Lambda+CD8 PE, CD3-+-CD14 ECD, CD34 APC, CD20+CD56 PC7, CD10 APC-A750, CD19 APC-A700, CD33 PC5.5, CD5 PB, and CD45 KO. Kappa/lambda expression was evaluated separately in CD19+, CD10+ and CD5+ B-cells. CD4+CD3+, CD8+CD3+,... (More)
Background We have designed one-tube 14-antibody 10-color flow cytometry (FCM) panel that would provide maximum information on lymphoid and myeloid cell subsets in bone marrow aspirates (BMA) from patients with cytopenia(s). Samples and Methods BMA from 8 normal donors, from 286 non-malignant hospital controls, 92 myelodysplastic syndromes (MDS), 47 myeloproliferative neoplasms (MPN), and from 14 MDS/MPN patients were investigated. One tube 14-monoclonal antibody (MAb) 10-fluorochrome panel included: kappa+CD4 FITC, Lambda+CD8 PE, CD3-+-CD14 ECD, CD34 APC, CD20+CD56 PC7, CD10 APC-A750, CD19 APC-A700, CD33 PC5.5, CD5 PB, and CD45 KO. Kappa/lambda expression was evaluated separately in CD19+, CD10+ and CD5+ B-cells. CD4+CD3+, CD8+CD3+, CD5+CD3+ T-lymphocyte subsets were enumerated. Blasts were evaluated using CD45/SSC and CD34 gating. The FCM score for MDS (sc. Ogata score) included CD34+ myeloblast and B-progenitor cluster size, myeloblast/lymphocyte CD45 expression, and granulocyte/lymphocyte SSC ratio. Results Abnormal lymphoid populations or increased plasma cells were found in 18 patients (4%). A 43/92 BMA from MDS and 7/14 from MDS/MPN patients had score >2. Score >2 had 92.5% positive predictive value for MDS/MDS-MPN diagnosis. Negative predictive value for MDS/MDS-MPN was 83% for scores under 3 and 88% for scores under 2. All but two of normal/hospital control samples had FCM score <3 (99%). Differences in scores between MDS & MDS/MPN and the control groups were statistically significant (P-<-0.0001). Conclusions Our one-tube FCM panel can be easily applied to screening for aberrant lymphoid populations and myelodysplasia-related features. MDS scores >2 are highly indicative of MDS or MDS-MPN.
(Less)
- author
- Rajab, Amr and Porwit, Anna LU
- publishing date
- 2015-07-01
- type
- Contribution to journal
- publication status
- published
- keywords
- bone marrow, flow cytometry, lymphoma, myelodysplastic syndrome
- in
- Cytometry Part B - Clinical Cytometry
- volume
- 88
- issue
- 4
- pages
- 8 pages
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:25664445
- scopus:84932200033
- ISSN
- 1552-4949
- DOI
- 10.1002/cyto.b.21233
- language
- English
- LU publication?
- no
- id
- 4a901211-6f5f-4407-a3e1-55c8ec6403c1
- date added to LUP
- 2019-05-22 09:44:27
- date last changed
- 2024-08-07 18:27:13
@article{4a901211-6f5f-4407-a3e1-55c8ec6403c1, abstract = {{<p>Background We have designed one-tube 14-antibody 10-color flow cytometry (FCM) panel that would provide maximum information on lymphoid and myeloid cell subsets in bone marrow aspirates (BMA) from patients with cytopenia(s). Samples and Methods BMA from 8 normal donors, from 286 non-malignant hospital controls, 92 myelodysplastic syndromes (MDS), 47 myeloproliferative neoplasms (MPN), and from 14 MDS/MPN patients were investigated. One tube 14-monoclonal antibody (MAb) 10-fluorochrome panel included: kappa+CD4 FITC, Lambda+CD8 PE, CD3-+-CD14 ECD, CD34 APC, CD20+CD56 PC7, CD10 APC-A750, CD19 APC-A700, CD33 PC5.5, CD5 PB, and CD45 KO. Kappa/lambda expression was evaluated separately in CD19+, CD10+ and CD5+ B-cells. CD4+CD3+, CD8+CD3+, CD5+CD3+ T-lymphocyte subsets were enumerated. Blasts were evaluated using CD45/SSC and CD34 gating. The FCM score for MDS (sc. Ogata score) included CD34+ myeloblast and B-progenitor cluster size, myeloblast/lymphocyte CD45 expression, and granulocyte/lymphocyte SSC ratio. Results Abnormal lymphoid populations or increased plasma cells were found in 18 patients (4%). A 43/92 BMA from MDS and 7/14 from MDS/MPN patients had score >2. Score >2 had 92.5% positive predictive value for MDS/MDS-MPN diagnosis. Negative predictive value for MDS/MDS-MPN was 83% for scores under 3 and 88% for scores under 2. All but two of normal/hospital control samples had FCM score <3 (99%). Differences in scores between MDS & MDS/MPN and the control groups were statistically significant (P-<-0.0001). Conclusions Our one-tube FCM panel can be easily applied to screening for aberrant lymphoid populations and myelodysplasia-related features. MDS scores >2 are highly indicative of MDS or MDS-MPN.</p>}}, author = {{Rajab, Amr and Porwit, Anna}}, issn = {{1552-4949}}, keywords = {{bone marrow; flow cytometry; lymphoma; myelodysplastic syndrome}}, language = {{eng}}, month = {{07}}, number = {{4}}, pages = {{253--260}}, publisher = {{John Wiley & Sons Inc.}}, series = {{Cytometry Part B - Clinical Cytometry}}, title = {{Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia-related features with one 10-color 14-antibody screening tube}}, url = {{http://dx.doi.org/10.1002/cyto.b.21233}}, doi = {{10.1002/cyto.b.21233}}, volume = {{88}}, year = {{2015}}, }